Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426]

Lung Cancer. 2024 Feb:188:107450. doi: 10.1016/j.lungcan.2023.107450. Epub 2023 Dec 30.
No abstract available

Publication types

  • Published Erratum